# Cel-Sci Corporation > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Cel-Sci Corporation). ## Overview CEL-SCI Corp. is a late-stage biotechnology company focused on developing immune-system-based therapies for cancer and other diseases. Its lead program is Multikine, an investigational immunotherapy for head and neck cancer, which the company has advanced through a long Phase III development program and into manufacturing readiness for potential regulatory filings. CEL-SCI also owns the LEAPS technology platform, which it is using to develop CEL-4000 as a vaccine treatment for rheumatoid arthritis. The company currently has no approved commercial products and is still dependent on financing activities while it seeks regulatory approvals and potential licensing opportunities. ## Products & services • Multikine investigational immunotherapy for head and neck cancer • LEAPS immunotherapy platform • CEL-4000 peptide-based vaccine candidate for rheumatoid arthritis • Clinical development and regulatory filing activities • Dedicated biologics manufacturing capability for Multikine - **Lead oncology biologic** (80%) — Multikine is CEL-SCI's principal investigational product for head and neck cancer and the main focus of its clinical and regulatory work. - **Preclinical immunotherapy platform** (15%) — LEAPS is a platform technology used to generate next-generation immune-based candidates, including CEL-4000. - **Manufacturing and development infrastructure** (5%) — The company operates a dedicated biologics manufacturing facility and related development capabilities to support clinical supply and future commercialization. - Multikine investigational immunotherapy for head and neck cancer - LEAPS (Ligand Epitope Antigen Presentation System) platform - CEL-4000 peptide-based vaccine candidate for rheumatoid arthritis - Clinical trial design, execution, and regulatory support - Dedicated biologics manufacturing facility for Multikine ## Customers CEL-SCI does not currently sell approved products to end customers, so its near-term 'customers' are primarily regulators, clinical investigators, and potential licensing or commercialization partners. The company’s most concrete commercial counterparty disclosed in the reports is Teva Pharmaceutical Industries, which has rights to market Multikine in Israel and Turkey if the product is approved. In the future, if Multikine is approved, the buyers would likely include hospitals, oncology treatment centers, and national or private payors that reimburse cancer therapies. For its platform assets, CEL-SCI is also positioning itself for licensing arrangements rather than direct broad-based product sales. - **Regulatory authorities** (primary) — FDA, SFDA, and other agencies review Multikine and determine whether CEL-SCI can commercialize its products. - **Commercial licensing partner** (primary) — Teva and related affiliates hold territorial rights to market and sell Multikine in selected countries if approved. - **Healthcare providers** (secondary) — Hospitals and oncology treatment centers would administer Multikine if it reaches market approval. - **Payors and reimbursement bodies** (secondary) — Government and private insurers would determine whether Multikine is covered and at what reimbursement level. - **Potential licensing partners** (emerging) — Pharmaceutical companies may license CEL-SCI technology or participate in future oncology indications. - Regulatory agencies that must approve Multikine before commercialization - Clinical trial sites and investigators running CEL-SCI studies - Teva and affiliated partners for Israel, Turkey, Serbia, and Croatia rights - Hospitals and oncology centers that would use Multikine if approved - Government and private payors that determine reimbursement for biologics - Potential licensing partners for CEL-SCI technology and know-how ## Geography CEL-SCI is headquartered in the United States and its core development, regulatory, and manufacturing activities are centered there. The company is pursuing a U.S. Biologics License Application strategy for Multikine while also planning filings in Canada, the United Kingdom, Europe, and Saudi Arabia. Commercial rights have already been licensed in Israel, Turkey, Serbia, and Croatia through Teva and related affiliates, showing that the company is using regional partners to extend its reach. Because CEL-SCI has no meaningful product revenue yet, geography mainly affects regulatory pathways, clinical execution, and future commercialization optionality rather than current sales mix. - United States is the main base for R&D, manufacturing, and regulatory work - U.S. BLA pathway is central to Multikine's commercialization plan - Canada, United Kingdom, and Europe are targeted future filing markets - Saudi Arabia is a recent regulatory target through a local partner - Israel, Turkey, Serbia, and Croatia are licensed territories for Teva - Geography matters mainly through regulatory approvals and partner-led market access ## Strategy CEL-SCI's strategy is centered on completing the regulatory package for Multikine and converting years of clinical development into a potential first commercial product. A key priority is maintaining manufacturing readiness, as the company has invested in a dedicated facility and completed commissioning to support a planned BLA submission and future supply needs. The company is also broadening regulatory optionality by pursuing filings in multiple jurisdictions and by using regional partners such as Teva and Dallah Pharma to extend market access without building a large commercial organization. In parallel, CEL-SCI continues to fund operations primarily through equity issuance and warrants, reflecting a strategy of preserving development continuity until a licensing or approval event can create revenue. - **Multikine regulatory submission and approval** (short-term) — Approval is the main path to first product revenue and validates the company's core asset. - **Manufacturing and supply readiness** (short-term) — A biologics launch requires validated production capacity and reliable clinical/commercial supply. - **Geographic partnering and market access** (medium-term) — Partner-led commercialization reduces CEL-SCI's need for a large sales force and expands reach. - **Pipeline diversification through LEAPS** (long-term) — A second platform could reduce dependence on Multikine and create future partnering opportunities. - Advance Multikine toward regulatory approval in the United States - Maintain manufacturing readiness for clinical supply and future launch - Pursue filings in Canada, the United Kingdom, Europe, and Saudi Arabia - Use regional partners to commercialize in selected territories - Keep the LEAPS platform alive as a second pipeline option - Fund operations through equity and warrant financing until revenue begins ## Risks CEL-SCI faces substantial development-stage risk because its lead product is still investigational and has not been approved by the FDA or other regulators. The company is exposed to long and expensive clinical and regulatory timelines, and any delay or failure in the confirmatory study, BLA process, or foreign filings could materially defer commercialization. Even if approved, Multikine would still face reimbursement risk because payors may challenge pricing or decide the therapy is not cost-effective enough for coverage. As a small biotech with no meaningful product revenue, CEL-SCI also depends on external financing, so dilution, capital-market volatility, and liquidity constraints are major business risks. More broadly, the company is exposed to manufacturing validation risk, partner execution risk in licensed territories, and general biotech industry risks such as clinical failure, regulatory changes, and patent or exclusivity challenges. - **Regulatory approval failure or delay for Multikine** [critical] — The company has no approved products and depends on Multikine to create commercial revenue. - **Reimbursement and pricing pressure** [high] — Even approved biologics can face cost-effectiveness scrutiny and limited coverage. - **Financing and dilution risk** [high] — Operations have historically been funded through equity, warrants, and loans. - **Manufacturing and validation risk** [high] — Biologics require validated production processes and reliable supply before launch. - **Partner and territory execution risk** [medium] — Commercial rights in some countries depend on third-party partners' regulatory and sales efforts. - Multikine may never receive regulatory approval, delaying or eliminating revenue - Clinical trial outcomes may not support commercialization or reimbursement - Payors may refuse coverage or demand pricing concessions for a new biologic - The company depends on equity financing, creating dilution and liquidity risk - Manufacturing validation or supply issues could disrupt clinical or launch plans - Partner execution risk exists in licensed territories such as Israel and Turkey - Biotech regulatory changes could increase compliance cost and delay approvals ## Accounting CEL-SCI's financial statements are heavily shaped by development-stage accounting rather than product revenue accounting, because the company has not yet launched a commercial product. Research and development spending is a major judgment area, especially for clinical trial costs, manufacturing scale-up, and platform development, and these costs can fluctuate materially as programs advance. Lease accounting is also important because the company operates a dedicated manufacturing facility, and the estimated lease term and incremental borrowing rate affect right-of-use assets and lease liabilities. Stock-based compensation is another meaningful item because the company uses equity awards to conserve cash, which can create non-cash expense and affect comparability across periods. Investors should also watch for going-concern and liquidity-related disclosures, since the company relies on external financing and may continue to incur losses until a product is approved or licensed. - **Research and development expense recognition** — Affects operating loss and period-to-period comparability - **Lease accounting for manufacturing facility** — Affects balance sheet lease assets/liabilities and interest/occupancy expense - **Stock-based compensation** — Affects reported G&A expense and dilution analysis - **Going-concern and liquidity assessment** — Important for evaluating solvency and future dilution risk - R&D expense reflects clinical trial, manufacturing, and platform development costs - Stock-based compensation can be significant and is non-cash - Lease accounting affects the manufacturing facility right-of-use asset and liability - Incremental borrowing rate estimates influence lease valuation - No commercial revenue means results are driven by operating expense timing - Liquidity and going-concern judgments are important because funding comes from equity --- *Last updated: 2026-08-11T04:46:25.665937+00:00*